• Artelo Biosciences reported positive nonclinical results for ART27.13 in a paclitaxel-induced peripheral neuropathy model.
• Repeated dosing reduced neuropathic pain behaviors, including mechanical allodynia, thermal hyperalgesia, in male and female animals.
• Data supports potential expansion into oncology supportive care for chemotherapy-induced neuropathic pain, beyond its Phase 2 CACS program.
• Interim CAReS Phase 2 findings showed trends toward improved body weight, lean body mass, activity, with favorable safety up to 1,300 µg/day.
• Pain endpoints were added to CAReS to assess whether the analgesic signal translates clinically.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.